Ibuprofen Tablets Bp 600mg
Product Summary
1 Trade Name of Medical Product Ibuprofen Tablets BP 600mg.
2 Qualitative and Quantitative Composition
Each tablet contains 600mg of Ibuprofen BP.
3 Pharmaceutical Form
Tablets.
Clinical Particulars
4.1. Therapeutic Indications
Ibuprofen is indicated for its analgesic and anti-inflammatory effect in rheumatoid arthritis (including juvenile rheumatoid arthritis or Still Disease), ankylosing spondylitis, osteoarthritis and non-rheumatoid arthropathies.
In non-articular rheumatic conditions, Ibuprofen is indicated in periarticular conditions, e.g. frozen shoulder, bursitis, tendinitis, tenosynovitis and low back pain.
Ibuprofen can be used in soft-tissue injuries, e.g. sprains and strains.
It is also indicated for the relief of mild to moderate pain, e.g. dental and post operative pain and dysmenorrhoea.
Ibuprofen is also indicated for the relief of migraine.
4.2 Posology and method of administration
For oral administration
To be taken preferably with or after food.
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see Section 4.4).
Adults:
Initial dose is 1200 mg daily in divided doses. Some patients can be maintained on 600-1200 mg daily. In severe or acute conditions it may be advantageous to increase the dosage, provided that the total daily dosage does not exceed 2400 mg in divided doses.
Elderly:
The elderly are at increased risk of the serious consequences of adverse reactions. If an NSAID is considered necessary, the lowest effective dose should be used and for the shortest possible duration. The patient should be monitored regularly for gastro-intestinal bleeding during NSAID therapy.
Children Over 12 years:
Dose is 20 mg/kg body weight daily except in children weighing less than 30 kg where the total dose in 24 hours should not exceed 500 mg.
Children Under 12 years:
Dose is 20 mg/kg body weight daily except in children weighing less than 30 kg where the total dose in 24 hours should not exceed 500 mg.
For pharmacy use, the MD is 400 mg and the MDD is 1200 mg.
4.3 Contraindications
Ibuprofen should not be given to patients:
• with active or history of recurrent peptic ulceration/haemorrhage (two or more distinct episodes of proved ulceration or bleeding)
• with a hypersensitivity to ibuprofen or to any of the ingredients in the drug
• in whom aspirin, ibuprofen or other non-steroidal anti-inflammatory drugs induce the symptoms of asthma, rhinitis, angiodema or urticaria
• with a history of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy
• with severe heart failure, hepatic failure and renal failure (see section 4.4)
• during the last trimester of pregnancy (see section 4.6)
4.4 Special warnings and precautions for use
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see Section 4.2, and GI and cardiovascular risks below).
The use of ibuprofen with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided (see section 4.5).
Elderly:
The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2)
Respiratory disorders
Caution is required if administered to patients suffering from, or with a previous history of bronchial asthma since NSAIDs have been reported to cause bronchospasm in such patients.
Cardiovascular, Renal and Hepatic Impairment:
The administration of an NSAID may cause a dose dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those taking diuretics and the elderly. Renal function should be monitored in these patients (see also section 4.3).
There is a risk of renal impairment in dehydrated children and adolescents. Cardiovascular and cerebrovascular effects:
Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.
Clinical trial data suggest that use of ibuprofen, particularly at a high dose (2400mg daily) and in long-term treatment may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen(e.g. <1200mg daily) is associated with an increased risk of myocardial infarction.
Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with ibuprofen after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).
Gastrointestinal bleeding, ulceration and perforation:
GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events.
The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and section 4.5).
Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.
Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or antiplatelet agents such as aspirin (see section 4.5).
When GI bleeding or ulceration occurs in patients receiving ibuprofen, the treatment should be withdrawn.
NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn’s disease) as these conditions may be exacerbated (see section 4.8).
SLE and mixed connective tissue disease:
In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may be an increased risk of aseptic meningitis (see section 4.8).
Dermatological:
Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Ibuprofen should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.
Impaired female fertility:
The use of ibuprofen may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of ibuprofen should be considered.
4.5 Interaction with other medicinal products and other forms of interaction
Care should be taken in patients treated with any of the following drugs as interactions have been reported in some patients.
Other analgesics including cyclooxygenase-2 selective inhibitors: Avoid concomitant use of two or more NSAIDs (including aspirin) as this may increase the risk of adverse effects (see section 4.4).
Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1).
Anti-hypertensives: Reduced anti-hypertensive effect.
Diuretics: Reduced diuretic effect. Diuretics can increase the risk of nephrotoxicity of NSAIDs.
Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels.
Lithium: Decreased elimination of lithium.
Methotrexate: Decreased elimination of methotrexate. Concomitant administration of ibuprofen with moderate and high doses of Methotrexate may lead to serious or fatal methotrexate toxicity. Patients with reduced renal function may be at additional risk of toxicity from the combination even when low doses of methotrexate (< 20 mg/week) are used.
Ciclosporin: Increased risk of nephrotoxicity.
Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.
Corticosteroids: Increased risk of gastrointestinal ulceration or bleeding (see section 4.4).
Anti-coagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section 4.4).
Quinolone antibiotics'. Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.
Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): Increased risk of gastrointestinal bleeding (see section 4.4).
Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus.
Zidovudine: Increased risk of haematological toxicity when NSAIDs are given with zidovudine. There is evidence of an increased risk of haemarthroses and haematoma in HIV (+) haemophiliacs receiving concurrent treatment with zidovudine and ibuprofen.
4.6 Pregnancy and lactation
Pregnancy:
Congenital abnormalities have been reported in association with NSAIDs administered in man; however, these are low in frequency and do not appear to follow any discernible pattern. Because of the known effects of NSAID’s on the foetal cardiovascular system (closure of ductus arteriosus), use during late pregnancy should be avoided. The onset of labour may be delayed and the duration increased with an increased bleeding tendency in both mother and child (see section 4.3). NSAIDs should not be used during the first two trimesters of pregnancy or labour unless the potential benefit to the patient outweighs the potential risk to the foetus.
Lactation:
In the limited studies so far available, NSAIDs can appear in breast milk in very low concentrations. NSAIDs should, if possible, be avoided when breastfeeding.
See section 4.4 Special warnings and precautions for use, regarding female fertility.
4.7 Effects on ability to drive and use machines
Undesirable effects such as dizziness, drowsiness, fatigue, visual disturbances or headaches are possible after taking NSAIDs. If affected patients should not drive or operate machinery.
4.8 Undesirable effects
Gastrointestinal: The most commonly observed adverse events are gastrointestinal in nature. Ulcers (e.g. duodenal, gastric and peptic), perforation or GI bleeding, sometimes fatal, particularly in the elderly, may occur (see section 4.4). Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, anorexia, indigestion, heartburn, abdominal pain, melaena, haematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn’s disease (see section 4.4) have been reported following administration. Less frequently gastritis has been observed. Pancreatitis has been reported very rarely.
Hypersensitivity: Hypersensitivity reactions have been reported following treatment with NSAIDs. These may consist of (a) non-specific allergic reaction and anaphylaxis, (b) respiratory tract reactivity comprising of asthma, aggravated asthma, bronchospasm or dyspnoea, or (c) assorted skin disorders, including rashes of various types, pruritis, urticaria, purpura, angioedema and, more rarely exfoliative and bullous dermatoses (including epidermal necrolysis and erythema multiforme).
Cardiovascular and cerebrovascular:
Oedema, hypertension and cardiac failure have been reported in association with NSAID treatment.
Clinical trial and epidemiological data suggest that use of ibuprofen, particularly at a high dose (2400mg daily) and in long term treatment may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see Section 4.4).
Other adverse events reported less commonly include:
Renal: Nephrotoxicity in various forms including interstitial nephritis, nephrotic syndrome and renal failure.
Hepatic: Abnormal liver function, hepatitis and jaundice.
Neurological and special senses: Visual disturbances, optic neuritis, headaches, paraesthesia, dizziness, tinnitus, drowsiness, reports of aseptic meningitis (especially in patients with existing autoimmune disorders, such as systemic lupus erythematosus, mixed connective tissue disease), with symptoms such as stiff neck, headache, nausea, vomiting, fever or disorientation (see section 4.4), depression, confusion, hallucinations, vertigo, fatigue and malaise. Very rarely, toxic amblyopia has occurred which recovered on cessation of treatment.
Haematological: Thrombocytopenia, neutropenia, blood dyscrasia e.g. agranulocytosis, aplastic anaemia and haemolytic anaemia.
Blood dyscrasias:
Patients should be warned about the onset of sore throats, bruising or bleeding, mouth ulcers, fever, or malaise, and should be instructed to stop the drug and to seek medical advice immediately. In such patients, blood cell counts should be performed immediately, particularly when there is clinical evidence of infection.
Dermatological: Bullous reactions including Stevens Johnson Syndrome and Toxic Epidermal Necrolysis (very rare). Photosensitivity.
4.9. Overdose
In children ingestion of more than 400 mg/kg may cause symptoms. In adults the dose response effect is less clear cut. The half-life in overdose is 1.5-3 hours.
Symptoms
Most patients who have ingested clinically important amounts of NSAIDs will develop no more than nausea, vomiting, epigastric pain, or more rarely diarrhoea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more serious poisoning, toxicity is seen in the central nervous system, manifesting as drowsiness, occasionally excitation and disorientation or coma. Occasionally patients develop convulsions. In serious poisoning metabolic acidosis may occur and the prothrombin time/INR may be prolonged, probably due to interference with the actions of circulating clotting factors. Acute renal failure and liver damage may occur. Exacerbation of asthma is possible in asthmatics.
Management
Management should be symptomatic and supportive and include the maintenance of a clear airway and monitoring of cardiac and vital signs until stable. Consider oral administration of activated charcoal if the patient presents within 1 hour of ingestion of a potentially toxic amount. If frequent or prolonged, convulsions should be treated with intravenous diazepam or lorazepam. Give bronchodilators for asthma.
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Ibuprofen is a non-steroidal anti-inflammatory agent with analgesic and anti-pyretic activity.
It is an effective inhibitor of cyclooxygenase responsible for the biosynthesis of prostaglandins which forms part of the inflammatory process. It also inhibits the same enzymes in the gastric mucosa.
Experimental data suggest that ibuprofen may inhibit the effect of low dose aspirin on platelet aggregation when they are dosed concomitantly. In one study, when a single dose of ibuprofen 400 mg was taken within 8 h before or within 30 min after immediate release aspirin dosing (81 mg), a decreased effect of ASA on the formation of thromboxane or platelet aggregation occurred. However, the limitations of these data and the uncertainties regarding extrapolation of ex vivo data to the clinical situation imply that no firm conclusions can be made for regular ibuprofen use, and no clinically relevant effect is considered to be likely for occasional ibuprofen use.
Pharmacokinetic Properties
5.2
Ibuprofen is rapidly absorbed following oral administration. t MAX : approximately 2 hours
t Vi : 2 ± 0.5H
Clearance : 0.75 ± 0.20 ML.MIN -1KG-1
Vd : 0.15 1/KG
The excretion of Ibuprofen is rapid and complete. Greater than 90% of an ingested dose is excreted, and no Ibuprofen per se is found in urine.
The major metabolites are a hydroxylated and a carboxylated compound.
5.3 Preclinical Safety Data
Not applicable.
Pharmaceutical Particulars
6.1 List of Excipients
Pregelatinised starch, maize starch, aerosil, magnesium stearate, methylhydroxypropylcellulose, polyethylene glycol 6000, titanium dioxide, dioctyl sodium sulphosuccinate, erythrosine lake FD and C red no.3 - C 145430.
6.2 Incompatibilities
None known.
6.3 Shelf Life
36 months.
6.4 Special Precautions for Storage
Protect from light.
6.5 Nature and Contents of Container
Securitainers (white bodies, blue lids) containing either 21, 100, 250, 500 or 1000 tablets.
Packs of 5000 and 10,000 tablets for bulk supply (supplied in polybags, free from additives inside a cardboard outer container).
6.6 Instructions for Use/Handling
None.
Administrative Data 7. Marketing Authorisation Holder Waymade plc
Trading as Sovereign Medical Sovereign House Miles Gray Road Basildon
Essex SS14 3FR United Kingdom
8. Marketing Authorisation Number
PL 06464/1431
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
05/03/2009
10 DATE OF REVISION OF THE TEXT
30/03/2016